AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
Google to Move All Pixel Production Out of China by 2027 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts 
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
Shein Targets $26B-$27B Valuation for Hong Kong IPO 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook 
Add as a preferred source on Google
South Korea's bio-industry increased its value output by 16.2 percent to 12.32 trillion won in 2019 from 10.48 trillion won the previous year due to robust growth of the outsourced business.
According to data from the Korea Biotechnology Industry Organization, the value of outsourced services that include contract research organization (CRO) and contract manufacturing organization (CMO) businesses jumped 21.1 percent on-year.
South Korea's exports of bioproducts, which rose 28.1 percent on-year to 6.71 trillion won in 2019, largely contributed to the value output.
The exports consisted of biomedicine products accounting for 39 percent, followed by bio-related food at 35.8 percent, and bio services at 12.2 percent.
The exports of cytokine products, including biosimilars, surged 50.7 percent on-year in 2019.
